Whether the new drug for neuromyelitis optica spectrum disorder (NMOSD) can be reimbursed in Kore is gaining attention.

Dailypharm found that Roche Korea is carrying out pricing negotiations with the National Health Insurance Service for the reimbursement of its NMOSD treatment Ensprying (satralizumab).

The drug passed the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee review on the 3rd of this month.

The issue is whether the ‘fourth or later lines of therapy’ that were set as the standard for reimbursement listing will be accepted during pricing negotiations.

Enspryng first aimed to receive reimbursement by accep